Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Dinutuximab β plus lage dosis IL-2 na haplo-SCT bij gerecidiveerd neuroblastoom
mei 2023 | Neuro-oncologie, Stamceltransplantatie